Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael R Abern

Showing results (1-10 of 85) with videos related to

Pageof 9
Sort By:
Oncology (Williston Park, N.Y.)|June 21, 2019
Counterpoint: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer?Ikenna Madueke, Michael R Abern
Thescientificworldjournal|August 4, 2009
Peyronie's disease: evaluation and review of nonsurgical therapyMichael R Abern, Laurence A Levine
European Urology|June 19, 2013
Maintenance bacillus Calmette-Guérin: why is there continued debate?Brant A Inman, Michael R Abern
European Urology|September 29, 2012
Prostate cancer antigen 3 to select men for prostate biopsy: stop, go, or proceed with caution?Michael R Abern, Stephen J Freedland
European Urology|April 16, 2013
Interpreting a study on bladder cancer screeningBrant A Inman, Michael R Abern
Translational Andrology and Urology|April 13, 2018
A novel bladder cancer urinary biomarker: can it go where no marker has gone before?Ryan W Dobbs, Michael R Abern
The Journal of Urology|August 18, 2009
Ketoconazole and prednisone to prevent recurrent ischemic priapismMichael R Abern, Laurence A Levine
Translational Andrology and Urology|January 28, 2016
Refining treatment for the men who need it: lessons from the PIVOT trialMichael R Abern, Matvey Tsivian, Thomas J Polascik
Urologic Oncology|December 24, 2013
Clinical performance and utility of a DNA methylation urine test for bladder cancerMichael R Abern, Richmond Owusu, Brant A Inman
The Journal of Sexual Medicine|October 26, 2011
Combination of penile traction, intralesional verapamil, and oral therapies for Peyronie's diseaseMichael R Abern, Stephen Larsen, Laurence A Levine
Pageof 9

Showing results (1-10 of 85) with videos related to

Sort By:
Pageof 9
Oncology (Williston Park, N.Y.)|June 21, 2019
Counterpoint: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer?Ikenna Madueke, Michael R Abern
Thescientificworldjournal|August 4, 2009
Peyronie's disease: evaluation and review of nonsurgical therapyMichael R Abern, Laurence A Levine
European Urology|June 19, 2013
Maintenance bacillus Calmette-Guérin: why is there continued debate?Brant A Inman, Michael R Abern
European Urology|September 29, 2012
Prostate cancer antigen 3 to select men for prostate biopsy: stop, go, or proceed with caution?Michael R Abern, Stephen J Freedland
European Urology|April 16, 2013
Interpreting a study on bladder cancer screeningBrant A Inman, Michael R Abern
Translational Andrology and Urology|April 13, 2018
A novel bladder cancer urinary biomarker: can it go where no marker has gone before?Ryan W Dobbs, Michael R Abern
The Journal of Urology|August 18, 2009
Ketoconazole and prednisone to prevent recurrent ischemic priapismMichael R Abern, Laurence A Levine
Translational Andrology and Urology|January 28, 2016
Refining treatment for the men who need it: lessons from the PIVOT trialMichael R Abern, Matvey Tsivian, Thomas J Polascik
Urologic Oncology|December 24, 2013
Clinical performance and utility of a DNA methylation urine test for bladder cancerMichael R Abern, Richmond Owusu, Brant A Inman
The Journal of Sexual Medicine|October 26, 2011
Combination of penile traction, intralesional verapamil, and oral therapies for Peyronie's diseaseMichael R Abern, Stephen Larsen, Laurence A Levine
Pageof 9